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To address complications of pathogenic antibody or life-threatening ease (<1% coagulation activity) form inhibitors, which are typically
anaphylactic reactions in protein replacement therapy for patients high-titer and are almost exclusively confined to subjects with gene
with hemophilia or other inherited protein deficiencies, we have deletions or early stop codons (3). ITT protocols are less effective for
developed a prophylactic protocol using a murine hemophilia treatment of inhibitors to factor IX (F.IX) and sometimes have to be
B model. Oral delivery of coagulation factor IX fused with cholera interrupted because of development of nephrotic syndrome. Impor
toxin p-subunit (with or without a furin cleavage site; CTB-FFIX or tantly, studies found that up to 50% of patients with F.IX inhibitors
CTB-FIX), expressed in chloroplasts (up to 3.8% soluble protein or 0.4 may experience potentially ltfe-threatening anaphylactic reactions to
mg/g leaf tissue), bioencapsulated in plant cells, effectively blocked F.IX which also preclude the subject from home treatment and
formation of inhibitory antibodies (undetectable or up to 100-fold severely hinder ITI protocols (3). These acute severe and systemic
less than controls). Moreover, this treatment eliminated fatal ana
type I hypersensitive allergic reactions, often attributed to IgE for
phylactic reactions that occurred after four to six exposures to intra mation, have been reported for treatment of hemophilia A and B,
venous F.IX. Whereas only 20-25% of control animals survived after lysosomal storage disorders, and others (4-9). fro prophylactic pro
six to eight F.IX doses, 90-93% of F.IX-fed mice survived 12 injections tocols are currently available for prevention of these pathogenic
without signs of allergy or anaphylaxis. Immunostaining confirmed antibody responses.
delivery of F.IX to Peyer^s patches in the ileum. Within 2-5 h, feeding
Oral delivery of coagulation factors has long been discussed as a
of CTB-FFIX additionally resulted in systemic delivery of F.IX antigen.

This high-responder strain of hemophilia B mice represents a new
animal model to study anaphylactic reactions. The protocol was
effective over a range of oral antigen doses (equivalent to 5-80 pg
recombinant F.IX/kg), and controlled inhibitor formation and ana
phylaxis long-term, up to 7 months (-40% life span of this mouse
strain). Oral antigen administration caused a deviant immune re
sponse that suppressed formation of IgE and inhibitory antibodies.
This cost-effective and efficient approach of antigen delivery to the
gut should be applicable to several genetic diseases that are prone to
pathogenic antibody responses during treatment.
allergy | chloroplast | genetic disorders | oral tolerance | plant-made

therapeutics

Current
ofinfusion
the ofX-linked
disorder hemophilia
is basedtreatment
on intravenous (i.v.)
recombinant orbleeding
plasma
derived coagulation factor VIII (hemophilia A) or factor IX (hemo
philia B) concentrate. In a subset of patients, humoral immune re
sponses to the functional protein develop and pose a serious com

plication for factor replacement therapy. In hemophilia A, formation

of inhibitory antibodies (inhibitors) directed against factor VIII
(F.VTII), a helper-T-cell-dependent response, occurs in 20-30% of
patients (1). There is much progress in the risk assessment of inhibitor
formation in patients early in therapy, using a combination of geno

typing (e.g., determination of the underlying F.VIII mutation and
polymorphisms in the promoters of the cytokine genes IL-10 and
TNFoc), family history of inhibitor formation, ethnicity, and intensity
of early treatment (2). Inhibitors increase the risk for bleeding-related

morbidity and mortality. High-titer inhibitors (>5 Bethesda units,
BU/mL) prevent treatment with clotting factor product. Bypass re
agents, such as activated factor VII, are expensive and pose throm
botic risks. Inhibitors can be eliminated by immune tolerance in

duction (ITI) protocols, which are based on frequent high-dose
infusions of factor for months to several years, and often require
amounts of products exceeding $1,000,000.
The overall incidence of inhibitors is considerably lower in he
mophilia B (1.5-3%). However, 9-23% of patients with severe dis

potential approach to induce tolerance in hemophilia (10). However,
realization has been elusive, likely because of inefficient delivery of
the antigen to the gut-associated lymphoid tissue (GALT). There

fore, we sought to develop an alternative approach, using trans

plastomic technology as a means of efficient and potentially tolero
genic oral delivery of F.IX. This technology for robust expression and
bioencapsulation of therapeutic proteins is based on transformation
of plant cells by particle bombardment of plasmid DNA followed by
homologous recombination with chloroplast genomes, selection, and

regeneration of plants (11, 12). Transplastomic plants lack gene
silencing, regardless of accumulating > 100-fold higher transcripts
than in nuclear transgenic plants and accumulation of foreign pro
teins at levels >70% of total leaf protein (13-16). Consequently, we

and others have been able to produce high levels of several bio
pharmaceutical proteins and vaccine antigens via the chloroplast
system (11,17). Foreign proteins expressed in plant chloroplasts can
be efficiently delivered to the immune or circulatory system upon oral

delivery when they are fused with the transmucosal carrier cholera

toxin B subunit (CTB) (14,18,19).
Although the prokaryotic nature of the chloroplast may not
perform all of the posttranslational modifications required to pro
duce biologically active F.IX, we reasoned that optimal delivery of
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the polypeptide to the GALT via bioencapsulation by the plant cell
would result in tolerogenic antigen presentation that modulates
immune response upon i.v. administration of functional F.IX pro
tein. Results demonstrate that repeated oral delivery of chloroplast
derived F.IX suppressed inhibitor development and prevented life
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threatening anaphylactic reactions to F.IX replacement therapy in a

murine model of hemophilia B.

alone was inadequate to prevent steric hindrance). Transplastomic
lines with roots were transferred to jiffy pellets and kept under high

humidity initially for 2 weeks in a growth chamber before plants

Results

were moved to the greenhouse.

Construction of Chloroplast Transformation Vector. Both chloroplast

vectors pLD CTB-FIX and pLD CTB-FFIX (Fig. L4) used in this
study are based on the universal chloroplast vector pLD-Ctv that
targets the expression cassette into the spacer region between the trnl

and trnA genes of the chloroplast genome for integration via ho
mologous recombination (20). In the CTB-FIX construct, a glycine

proline-glycine-proline (GPGP) hinge was created between the
fusion elements to prevent steric hindrance, whereas in the CTB

FFIX construct, along with the GPGP hinge, a furin cleavage site was

also introduced. The CTB-FIX and CTB-FFIX fusion genes were

regulated by thepsbA promoter and 5' untranslated region (UTR) to
achieve hyperexpression, as demonstrated previously for several
other transgenes (21). The psbA 3' UTR placed at the 3' end of the
fusion gene imparted transcript stability. The aadA gene driven by the

tobacco plastid ribosomal operon promoter (?rrn) and the GGAG
ribosome binding site conferring spectinomycin resistance were used
for selection.

Regeneration of Transplastomic Plants and Evaluation of Transgene

Integration by Southern Blot Analysis. Transplastomic tobacco
plants were produced as described earlier (12, 22). Chloroplast
transgenic lines were examined by Southern blots to confirm site
specific transgene integration and to determine homoplasmy or
heteroplasmy. Digestion of total plant DNA from untransformed

plants (WT) with Hindlll generated a 7.67-kbp fragment when
hybridized with the 32P-labeled trnl-trnA flanking sequence probe,

indicating no integration of foreign DNA (Fig. 1 B and C). All
CTB-FIX transplastomic lines showed both 10.88-kb and 7.67-kb

fragments, indicating heteroplasmy, whereas all CTB-FFIX

transgenic lines showed only the 10.89-kb fragment, indicating
homoplasmy. Southern blots confirmed site-specific integration of
the transgenes into the spacer region between the trnl and trnA
genes (Fig. 1B and C). Homoplasmy in CTB-FIX transgenic lines
was not achieved even after additional rounds of selection. This
may be due to toxicity created by improperly folded F.IX due to
steric hindrance in the absence of a furin cleavage site (GPGP

pLD CTB-FIX Smal Xba I

E^f tml ^fP^ MdA ^'5liTR)[CTBtl Factor PC 3'UTR^)j tmA~^>
pLD CTB-FFIX Smal Xba I

CTB-FIX and CTB-FFIX Expression and Pentamer Assembly in Transgenic

Tobacco. Immunoblots probed with CTB antibody showed the
presence of an ~58-kDa fusion protein in both CTB-FIX and CTB
FFIX transplastomic lines. A similar banding pattern was observed
by immunodetection with FIX antibody (Fig. 1D and E). Pentamer
formation was observed in the native PAGE using CTB primary
antibody (Fig. IF). Quantitation of the fusion protein was carried
out by densitometry on Western blots of plant samples using known
amounts of purified CTB. The expression levels varied significantly

depending on the developmental stages and time of leaf harvest
(Fig. 2 A-C). Young (top five), mature (fully grown), and old
(bottom three) leaves in transplastomic plants were investigated.

Fig. 2 A-C show that transplastomic lines have higher F.IX
expression in mature leaves. Younger leaf cells contain fewer chlo

roplasts and the psbA promoter is developmental^ regulated;

therefore, expression levels were less than in mature leaves. Older
senescent leaves had lower accumulation of F.IX, probably due to
higher proteolytic activity. Likewise, F.IX expression was higher at
6 PM than at 10 AM because the psbA promoter and 5' untranslated

regions located upstream of the FIX gene cassette are known to
enhance translation in the light (15,16,23). Transplastomic lines of

CTB-FIX and CTB-FFIX had expression levels of up to 0.19% and
3.8% (0.4 mg/g of leaf tissue) fusion protein, respectively, in the total

soluble protein. Introduction of the furin cleavage site clearly sta
bilized FIX and enhanced its accumulation 20-fold.
Vibrio cholerae secretes an 86-kDa toxin that is made up of two
subunits, an a- and a p-subunit (CTB), that contains a binding site for
the plasma membrane receptor of the intestinal epithelial cells (GM1)

(24,25). GMl-ganglioside has been shown to be the receptor for CTB
protein in vivo (24), and a pentameric structure is required for binding
to GM1 receptor (25). As illustrated in Fig. 2D, GM1 ELISA confirms

that CTB-FIX and CTB-FFIX fusion proteins assembled properly to
form pentameric structures within chloroplasts, which are essential
for GMl-ganglioside receptor binding. This assay along with native
PAGE confirmed the correct folding and disulfide-bond formation of
CTB pentamers within transgenic chloroplasts.

Oral Delivery of F.IX Transplastomic Leaves Suppresses Inhibitor
Formation and Fatal Anaphylaxis in Hemophilia B Mice. Hemo
philia B mice with targeted F9 gene deletion on C3H/HeJ genetic
background form robust immune responses to human F.IX (hF.IX)
upon protein or gene therapy (26). Therefore, three experimental
groups received oral gavage of frozen powdered leaves (250 mg/

B 1 2 3 WT ^ WT 1 2 3 4dose) twice per week for 2 months, using leaves from untransformed
" : 7 67 kb

wS* ^^o.?K?

4^ 41 F kDa WT Y MO

(WT), CTB-FIX, or CTB-FFIX transplastomic plants (repre

75

kDa WT Y M O. 50

75

_

Dctb Ab m%% mm*
75

"* " *
7* F CTB CTB WT

FIX Ab kDa FRX RX

50 268CTBAb460 ,^
Fig. 1. Characterization of transplastomic plants. (A) Schematic repre

illrti rli ll bIf rli fli
10AM 2PM 6PM 10AM *PM 6PM

fell 8U_

sentation of chloroplast transformation vectors. Prrn, rRNA operon pro
moter; aadA, aminoglycoside 3'-adenylyltransferase gene; 5' UTR, promoter
and 5' untranslated region of psbA gene; 3' UTR, 3' untranslated region of
psbA gene. (B and C) Southern blot analysis of CTB-FIX and CTB-FFIX. WT,
untransformed; 1-4, transplastomic lines. (D and E) Western blot analysis of
10AM 2PM 6PM CTB-mX CTB-HX WT BSA
transplastomic lines expressing CTB-FIX and CTB-FFIX probed, with CTB
antibody and FIX antibody. WT, untransformed plant extract; Y, M, and O, Fig. 2. Protein analysis in transplastomic tobacco plants. Accum
plant extract from young, mature, and old transplastomic leaves, respec CTB-FFIX (A and B) and CTB-FIX (C) as a function of light and deve
tively. (F) Native PAGE. Total soluble protein extracted from transplastomic stage. (D) GM1 binding assay of CTB-FIX and CTB-FFIX tobacco trans
WT, untransformed; BSA, negative control. TSP, total soluble protei
leaves, resolved by native PAGE and probed with CTB antibody.
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exposures; Fig. 3C). In none of these mice
allergic or anaphylactic reactions. Bethes
complete to complete suppression of inhib

senting the equivalent of 0, 0.14, and 2 ug of recombinant

hF.IX-dose^-mouse"1, respectively). Dosage of CTB-FIX and

CTB-FFIX for each batch of ground leaf powder was determined
before each gavage and uniform doses were delivered. After
1 month, a therapeutic dose of recombinant hF.IX was given i.v.
once per week (1 IU per mouse) for 2 months, that is, extending
1 month beyond the feeding protocol (Fig. 3A). Two more groups
received i.v. injections of hF.IX only, without feeding.

fed with CTB-FIX (1 ? 0.5 BU/mL) or C
mL) as compared with background inhibit
philia B mice (no feeding, no treatment;
viving WT-fed and unfed mice had signifi
titers, which were similar for these group
8 BU/mL and 2.5 to 10 BU/mL, respective
We suspected that these data underrepres

In unfed animals (n = 11), severe allergic reactions were observed
starting with the fourth i.v. injection of hF.IX, at which time fatal
anaphylactic reactions started to occur, and continued subsequently

induced inhibitor titers in the control group

fatal hypersensitive responses likely had stro
To address these points, we first analyzed pla

with an incidence of 17-33% (Fig. 3B). Similarly, WT-fed mice
showed severe allergic reactions immediately following the fourth (2

hemophilia B mice after only four weekly

of 10 mice) and fifth injections (3 of 10 mice), including hunched
position, piloerection, slowing of movement, tachypnea, and bron
chospasms. During subsequent injections, ~50% of the mice had such

had substantially higher inhibitor titers of

the three of seven mice with the highest titers

administration (arrows in Fig. 3D). Second,

reactions. Moreover, starting from the sixth injection, 31-40%

vived a fifth injection received the sixth dos

of animals died within 30 min to several hours after i.v. injection of
hF.IX, apparently from respiratory arrest (Fig. 3C). We were able to
collect blood samples from five remaining mice immediately after the

with
case,
(Fig.
were

eighth i.v. injection, within 2 h after which three additional mice died.

In any case, 75-80% of mice treated with hF.IX were lost within six
to eight weekly injections (Fig. 3 B and C), unless antianaphylactic
drugs were given (see below).

D

Feeding

Month:

weekly i.v. infusions of hF.IX) while also

^=h

(250

mg;

very high (29-87 BU/mL; Fig. 3D).

Oral Administration of Bioencapsulated hF.
Formation Long Term. One month after t
one additional i.v. administration of hF.IX
CTB-FFIX-fed mice (i.e., 2 months after th
This resulted in an increase of inhibitors t
(Fig. 3E). Subsequently, treatment was res

In contrast, 90% of CTB-FIX- and 93% of CTB-FFIX-fed mice
(n > 14 per cohort) survived the initial 2-month period of eight
weekly hF.IX injections and even subsequent injections (total of 12

A

antihistamine and anti-platelet activat
all five mice survived without allergic
3B). Inhibitor titers were measured in

(three oral gavages per week). At the end of

twice/week)

|-1-1-?I
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be used to control inhibitor form
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Oral Administration of Bioencapsulated hF
of IgE and Inhibitors via an Immune Deviat
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Whereas IgGl titers in control mice correl
titers, there was no correlation in CTB-FI
7 which therefore had formed noninhibitory
noninhibitory antibodies in CTB-FFIX-fed

protein therapy, in contrast to the inhibitor
fed mice, did not cause enhanced clearance
o
>

the circulation (Fig. AF). The noninhibitor
2
o
prevent correction of coagulation activity
(a
s
Fig. 3. Prevention of inhibitor formation
and
of anaphylactictime),
reactions
partial
thromboplastin
which was
rais
g
against i.v. hF.IX by oral administration of
chloroplast
transgenic
plant after
3
to hF.IX
16-25%
of normal
at 30 min
a. i.v. in
Number of Injections 0 1 2 3
Time point

material in hemophilia B mice. (A) Feeding and hF.IX administration schedule.

5). Naive mice treated in parallel showed

(8) Survival of two control groups of unfed mice (starting with n = 11, solid line,
18% of normal at 30 min after treatment).
and n = 12 mice, dotted line). Mice of one cohort (solid line) that survived five

Importantly, three of seven control mice

injections (n = 5) received antihistamine/anti-PAF before a sixth injection of hF.
hF.IX
had
detectable
IgE titers,
IX (ahist/aPAF), resulting in 100% survival. injections
(C) Survival of
of mice
fed
with
WT(n =

were predictive
of subsequent
10 mice at the onset of protein therapy), CTB-FIX
(n = 17), or CTB-FFIX
(n = 15)

fatal respo
four of fiv
time-point
mice
(i.e., after
8 weekly
i.v.
received
a sixth
injection
concomitant
with

was protein.
found in
plant material as a function of the number Higher-titer
of i.v. injectionsIgE
of hF.IX
(D)

Inhibitor titers (in BU/mL) at 3-month
injections of hF.IX) in unfed (pooled from
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experiments),
WT-fed,
(Fig.
4B).
These control
mice CTB
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FlX-fed, and CTB-FFIX-fed. Additional controls: Titers in unfed mice are shown

IgGl (>40 pg/mL) and IgE formation, indic

that received antihistamine/anti-PAF before a sixth injection of hF.IX, that
administrations boosted Th2-driven antibody
were naive, or that received four hF.IX administrations. For the last, arrows
activation of additional B cells with class sw
indicate animals that died after a subsequent fifth injection. Each dot repre
This correlation was not seen in CT B-FFIXsents an individual animal. Horizontal bars indicate average titers for each
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IgGlformation
titers that
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have been
experimental group. (?) Long-term control
of inhibitor
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bio
with
IgE
AD). CTB-FIX/FFIX-f
encapsulated hF.IX following the indicatedated
schedule
for
oral(Fig.
administration
of
CTB-FFIX plant material and i.v. injectionof
of <40
hF.IX
ng/mL
protein.
(the
Numbers
background
indicate
of our ass
time points of blood collection. Below, average
inhibitor
titersreactions
(in BU/mLin
? rodents,
responses.
Allergic
SEM) are graphed for the indicated time points.
identified in hemophilic mice, in general

Vermaetal. PNAS | April 13,2010 | vol.107 | n

This content downloaded from 132.170.192.79 on Thu, 13 Dec 2018 14:24:17 UTC
All use subject to https://about.jstor.org/terms

C 160000 I | .?
a.

^ ,m00? i I 1 0<=x. 200000-1 ctb-fix/ffix

^ ***** # Unfed controls

cn

o> 140000 3 150000

^ 120000 ^ >< *

H 100000 ? 100000- ?
80000 ^

? eoooo- | 0<=x <5 50000- #

5 40000. I ~~_ 5 *
- I J.
I cn o^flL,-,-,-,-,-,-,-,

20000 T "I" I "" 0 100 200 300 400 500 600 700 800

0- * 5 ' IgE anti-hF.IX (ng/ml)

Groups: wt ctb-fix ctb- ahis/ Unfed (short- 9
ffix paf term treatment
#mice: 5 15 14 5 7

g _?_! ? Fig. 4. Suppression of high-

^ 800] r^H 400 "9G2b directed against hF.IX. (A)

f 700 ~ 3so 7 (i.e., after 8 weekly i.v. injec

S 600 ?, 300 j I FFIX-fed mice. Additional unfe

2 ' ' x 250 1 ^'9* ^'ui^200'9^
titers for the s
I I next to data points from unfed m

?

300'

o>

-f-

?

150

n

100.

Groups:

.

.

.

'

200

*^

i

ioo

50

i

II

I

J9Am

I

I

I

h

i

0l__?L__dt_Jt_!_.
oll.l.l
wt
ctb-fix
ctb-ahis/
unfe

Ti'X

7

Ttreatment

# Unfed controls I? , , ,

mice

fed

'

fix8

with

CT

Cr- (?) Immune deviation induced by oral administration. lgG2b and

=-2ooooo-j ctb-fix/ffix 600 lr -?>- Naive (n=4) IgA titers are elevated in CTB-FIX-and CTB-F
f ~ soo-fv CTB.FF|X (n=5) pared with WT-fed and unfed control mice after

15000?" # S\ 400 \ -*-;-x-- [JjUf'K^ygjJ injections of hF.IX protein. (F) In compariso

2 100000- # ? 300 A \^ philia B mice or CTB-FFIX-fed mice, WT plant mat

| \s ^ 200 \ r658^^^^ with inhibitor development (shown are two individua
? 50000- * 100 K ^^^^^^ 5 and 7 BU) show enhanced clearance of i.v. injected hF.IX protein
& o-l i ^ q - ^ - - - - = = - (1 lU/mouse). Shown are hF.IX antigen levels in plasma as a
o 102030405060708090100 o s io is 20 25 function of time after i.v. injection. Data pointsfor naive and CTB

F.IX Inhibitor titer (BU/ml) Time (hrs) FFIX-fed mice are average ? SEM.

and PAF release for IgE-dependent reactions, whereas an alter
native, IgG-dependent pathway has also been described, which,
however, does not involve histamine (27). To address this point,
additional control mice received hF.IX administration under cov
erage with anti-PAF alone (i.e., without antihistamine), resulting in
fatal anaphylaxis in all three animals tested, thereby further sup
porting an IgE-dependent mechanism in the hemophilia B mice.
None of the WT-fed or unfed mice formed IgG2a against hF.IX,
thereby ruling out an IgG2a/complement-dependent mechanism of
anaphylactoid reactions. Whereas IgG2a formation was highly vari

able and inconsistent in CTB-FIX/CTB-FFIX-fed mice, tolerized
mice consistently had circulating low titers of TGF-0-dependent
antibodies IgG2b and IgA, the hallmark subclass of a mucosal anti
body response (Fig. AE).

CTB-FFIX Material Delivers hF.IX Antigen to the GALT and into the

Circulation. Feeding by CTB-FIX or CTB-FFIX material by itself
did not cause a detectable systemic antibody response against hF.
IX. Immunostaining demonstrated that feeding resulted in deliv
ery of hF.IX antigen to the ileum, predominantly to the interphase
between microfold (M) cells and CD1 lc+ dendritic cells in Peyer's

patches (Fig. 5 A and B). Within 2-5 h, feeding of CTB-FFIX

material also resulted in systemic delivery of hF.IX antigen to the
liver and into plasma (Fig. 5 D and F). In the case of unfed mice, no
signal was detected in ileum (Fig. 5C) or liver (Fig. 5E).

Discussion
Oral tolerance for hemophilia has been discussed for the past decade
but has not been realized, in part because of challenges in effective
delivery of coagulation factor antigen to the gut. A recent study con
cluded that the amount of coagulation factor required for feeding
would be cost-prohibitive even for mouse experiments and therefore
was not pursued (28). Here we used an alternative technology that
allows for efficient production, bioencapsulation, and delivery of an

tigens to the GALT (14,18,29,30).

Human F.IX was produced at a high level in plant chloroplasts as a
fusion protein. The CTB fusion ensures stability of the transgenic
protein in the chloroplast, and the nontoxic B subunit exhibits specific

and high-affinity binding to the oligosaccharide domain of ganglio
side GM1 (a lipid-based membrane receptor), thereby tethering the
protein to the plasma membrane of host cells of the intestinal epi
thelium upon release from the plant cells in the ileum (18, 31).
Priming with CTB-FIX via an oral route reduced Th2-dependent
antibody responses against i.v. hF.IX, and in particular protected from
IgE formation, thereby eliminating allergic and anaphylactic reac
tions. Moreover, reintroduction of the antigen via the oral route suc
cessfully controlled inhibitor formation long-term without a need for
immune-suppressive drugs. Interestingly, plant materials expressing
20-fold different antigen levels were effective, which should facilitate
clinical translation. The furin cleavage site, which directs release and
exocytosis of the fused protein from gut epithelia, was not required for
treatment (but improved expression and accumulation of FIX in plant
cells). These results imply that introduction of F.IX to the GALT was
key to successful immune-modulatory therapy. It is generally thought
that persistence of the antigen is required to maintain tolerance. Thus,
it is likely that oral delivery has to be repeated beyond the induction
phase, perhaps every 2 months, to maintain hyporesponsiveness long

term. It should be possible to optimize the protocol so that less
intensive repeated oral dosing is effective for maintenance.
Repeated injections of hF.IX caused fatal reactions in most control
animals, so that only mice survived that were either low responders or,
possibly, spontaneously controlled the pathogenic antibody response.

The magnitude of the antibody response was unmasked by pharma
ceutical blockage of Wstamine release, thereby allowing animals to
survive despite high production of IgE against hF.IX. Tests to detect
IgE responses in patients with hemophilia have been developed, such

as RAST (radioallergosorbent test) (9). However, there are no pro
tocols for preventing or suppressing IgE formation, nor has there been

an animal model that rnimics this aspect of hemophilia pathophysi
ology. Similar to observations in humans, the strain of mice we iden
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risks of immunotoxicities and insertional mutagenesis; imm

suppressive drugs have side effects and increase the risk for op
tunistic infections, and long-term consequences of use in pedia
patients are unclear. Administration of peptides to mucosal surf
has also been described, which, however, is complicated in an

bred population because it requires knowledge of CD4+ T-c
epitopes (37).
The chloroplast system overcomes major limitations of pro

production by elimination of highly expensive fermentation and
fication systems, cold storage, transportation, and sterile injectio

Genetically modified chloroplast genomes of most crops are m

nally inherited, and the absence of any reproductive structures of

efficient foreign gene containment (38, 39) and therefore f
tates their safe production in the field (23). Plant cells pro
bioencapsulation and protect therapeutic proteins from de
dation in the stomach from acids and enzymes (30). Plants
reduce concerns about pathogen contamination as may be the
for production of proteins in transgenic animals. Whereas t
hFIX hFIX ?v-'
v->
2 hrs 5 hrs
initial studies were carried out in nonfood tobacco plants, the
tuce chloroplast transformation system has been well-develo
Fig. 5. Delivery of hF.IX antigen to the GALT and into circulation. (A-E)
for expression of human therapeutic proteins (14,16).
Immunostains (original magnification: 200x). (A) Peyer's patch and villi of
With green),
the recent development of novel protein replaceme
ileum of CTB-FFIX-fed mouse stained for hF.IX (red), M cells (UEA-1,

for genetic diseases, more reports are coming forwar
and CD11c (blue). Inset shows zoom-in on part of Peyer's patchtherapies
with positive
immunotoxicities
caused by protein infusion. Oral administra
hF.IX staining. (B) Peyer's patch and villi of ileum of CTB-FFIX-fed
mouse
stained for hF.IX (red), F4/80+ macrophages (green), and nuclei
blue).
of(DAPI,
transplastomic
plant tissue provides an avenue for preven
(C) Negative control: stain for hF.IX (red) and nuclei (DAPI; blue)
ileum of of pathogenic antibody responses and anaphyla
andincontrol
unfed mouse. (D and E) Stain for hF.IX (green) and nuclei (DAPI;
blue) of liver
reactions
to systemically delivered therapeutic proteins.
of CTB-FFIX-fed (D) and unfed (?) mouse. (F) In two independent experi

and Methods
ments, hF.IX antigen was detectable in plasma in two of threeMaterials
mice 2 or 5 h
after oral gavage with CTB-FFIX material.
Vector Construction. Two CTB fusion constructs were made with human fa

IX (FIX). To prevent steric hindrance, a glycine-proline-glycine-proline (GP
hinge was introduced between the CTB and FIX in one of the constructs. A fu

tified as prone to anaphylactic reactions has an F9 genecleavage
deletion
(8).was
A also introduced along with the GPGP hinge in the sec
site
construct.
The cDNA sequence encoding F.IX was obtained from the Amer
lack of prior reports on anaphylactic reactions to coagulation
factors
Type Culture
Collection and amplified using sequence-specific restrictionmay be because protein replacement therapy has been largely
studied
flanking
primers and a cDNA clone of human factor IX as template. The
using F.VIII infusions to hemophilia A mice (which, similar
to human
product was then cloned into the pCR Bluntll Topo vector (Invitrogen) and
treatment, is less likely to cause anaphylaxis). Hemophilia B mice were

sequence was verified. Following Smal/Xbal digestion, the FIX gene was lig

primarily used for gene therapy studies and/or bredinto
on the
C57BL/6
pLD Ctv 5CP chloroplast transformation vector (14) to create pLD
background (which shows weaker immune responses to
FIXF.IX)
(only (32).
a GPGP hinge between CTB and FIX) and pLD-CTB FFIX (with a G
Symptoms in the hemophilia B mice were similar tohinge
IgE-mediated
and furin cleavage site between CTB and FIX) vectors.
severe anaphylactic reactions observed in the treatment of other ge

netic diseases, including hemophilia A and the lysosomal
storage
Regeneration
of Transplastomic Plants and Confirmation of Transgene Integra
by Southern
Blot. Transplastomic plants using chloroplast expression vectors p
disorders Pompe disease (acid oc-glucosidase deficiency)
and Fabry
and pLD
disease (oc-galactosidase A deficiency) (5-7, 33). In CTB-FIX
treatment
of CTB-FFIX were regenerated as described elsewhere (12,
plant DNA (1-2 ug) isolated from leaves using a Qiagen DNeasy P
hemophilia B, strong evidence has been provided forTotal
IgE-mediated
Mini Kit was digested with Hindlll, and Southern blot analysis was carried
anaphylactic reactions (9,34). However, IgG/complement-mediated
to confirm integration and determine homoplasmy as described previo
mechanisms have also been proposed (4), and IgE formation
may
(22). Southern
blots were hybridized with a [32P]oc[dCTP]-labeled
o chlorop
therefore not be the only source of anaphylactoid
reactions
in probe (0.81 kb) containing the trn\-trnA genes.
flanking
sequence
The tr
2
o
humans with hemophilia.
plastomic plants with roots were transferred to a greenhouse
S as descr

previously
(12).
Protection of hemophilia B mice from inhibitor and IgE
responses
?
involved a deviant immune response characterized by suppression of
3
a.
Immunoblot
Analysis.
Young,
mature,
and
old
leaves
from
transformed
p
IgE and of high-titer IgGl, formation of nonneutralizing antibodies
grown in (albeit
a greenhouse were collected at 10 AM, 2 PM, and 6 PM. Chlorop
instead of inhibitors, and production of additional Ig subclasses
derived CTB-FIX and CTB-FFIX proteins were extracted from 100 mg of
at very lower titers). Interestingly, the presence of nonneutralizing

dered leaf material as described earlier (12,22). Equal amounts of total pro
along with known amounts of purified bacterial CTB (Sigma) were separa
production by CD4+ T cells, that is, by Th2 cells, promotes
both IgGl
by SDS/PAGE
and transferred to a nitrocellulose membrane by electroblot
and IgE class switching. However, it has been proposed
that gut with rabbit anti-CTB primary polyclonal antibody (1:3,0
Immunoblotting

antibodies has also been described in clinical ITI protocols (4). IL-4

associated regulatory T cells expressing IL-10 may suppress
IgE horseradish
for
Sigma) and
peroxidase (HRP) -conjugated donkey anti-rab
antibody
(1:5,000; Southernbiotech) was used for densitom
mation (35). Our findings on induction of IgG2b and secondary
IgA suggest
a
(12, 16,
role for TGF-p, possibly derived from Th3 cells, in analysis
modulation
of 19). A SuperSignal West Pico HRP Substrate Kit (Pierce
employed for detection of chemiluminescence signal by exposure to f
F.IX-specific B-cell activation.

Fusion protein was also detected using goat anti-human factor IX (1:3,

Notably, the response to the alio- or autoantigen introduced to the
Enzyme Research) antibody followed by donkey anti-goat IgGGALT by oral administration of chloroplast transgenic plant material

conjugated secondary antibody (1:5,000; Santa Cruz Biotechnology). N

modulates responses to the antigen in other tissues,PAGE
which
was we
also ex
carried out and fusion protein was detected as described ab
ploited to develop oral tolerance protocols (14). TheGM1
oral
delivery
receptor
binding assays were performed as described previously (40
protocol described here offers solutions for complications encoun
tered with alternative strategies such as gene transfer
or transient
Animal
Experiments. Male C3H/HeJ mice with targeted deletion of the F9
(hemophilia
B mice, 8-10 weeks old at the onset of experiments) were
immune-suppressive regimens (36). Genetic manipulation
poses
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as published (26, 41). Animals were housed under special pathogen-free

before addition to microtiter plates coated with hF.IX protein. Statistical com

conditions at the University of Florida and treated under Institutional Ani
mal Care and Use Committee-approved protocols. The leaf material for oral
delivery was ground in liquid nitrogen with mortar and pestle and stored at
-80 ?C until the day of administration. Oral doses (250 mg each) of either
untransformed or transgenic leaf material were resuspended in 200 pL of
sterile PBS and homogenized on ice for 5 min with an OMNI International
(GLH-2596) probe. The plant cell suspension was stored on ice until oral
delivery via oral gavage using a tuberculin syringe and a 20-G bulb-tipped

parisons between experimental groups were assessed with unpaired Student's t
test. Differences were considered signif icant and reported with *P < 0.05, **P <
0.01, ***P < 0.001, and so on.

gastric gavage needle (Popper and Sons) while maintaining the animals
under light anesthesia. Recombinant hF.IX (Benefix) was injected into the
tail vein at 1 IU (4-5 ug hF.IX) per mouse. Plasma samples were collected by
tail bleed into citrate buffer as described (26). For clearance studies, mice
were bled from the retro-orbital plexus using heparinized microcaplllary
tubes. To block anaphylactic reactions, 150 pg antihistamine (triprolidine;
Sigma) and 50 pg antiplatelet-activating factor (PAF) CV-3988 were coin
jected i.v. (in 100 pL PBS) 5 min before administration of hF.IX.

Antigen and Antibody Measurements. Plasma levels of hF.IX antigen were
measured by ELISA and inhibitory antibody titers were determined by Bethesda
assay as published (26). One Bethesda unit (BU) represents the degree of inhibition

Immunohistochemistry. Mice were fed with CTB-FFIX material (250 mg) twice
per day for 2 days and killed 5 h after the last gavage, and tissue was collected
as described (26). Cryosections (10-um thick) were fixed in acetone for 5 min,

air-dried, and then rehydrated in PBS. Sections were blocked with 2%
donkey serum in PBS for 30 min. Goat cc-hF.IX (1:400; Affinity Biologicals), rat

a-F4/80 (clone: C1:A3-1; 1:200; AbD Serotec), and biotinylated-a-CD11c
(1:200; BD Biosciences) were applied in 2% donkey serum for 30 min. After a
washing, tissue sections were incubated with secondary antibody Alex Fluor

488 donkey a-rat IgG, Alex Fluor-568 donkey (or FITC) oc-goat IgG, and
streptavidin-Alexa Fluor-350 (1:100 dilution; Invitrogen). Some sections were
incubated with FITC-labeled Ulex europaeus agglutinin (UEA-1; Vector Labs;

10 pg/mL) for 10 min before being washed and mounted with or without
DAPI. Images were captured using a Nikon Eclipse 80i fluorescence micro
scope and Retiga 2000R digital camera (Qlmaging) and analyzed with Nikon
Elements software.

that results in 50% residual coagulation activity. Immunocapture assays to
determine titers of hF.IX-specif ic Ig subclasses were as described using IgA, IgE,
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